Haploidentical Hematopoietic Stem Cell Transplantation in the Treatment of Hematological Malignancies Using CAMPATH-1H

Tehran University of Medical Sciences0 个研究点目标入组 10 人开始时间: 待定最近更新: 2018年2月22日

试验速览

暂无简介。

•Inclusion Criteria:
•Ages 5-50 years
•Acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL)
•Second remission (CR2) in standard risk patients or CR1 in cases with high-risk features (poor cytogenetic changes or secondary to myelodysplastic syndrome)
•Unavailability of HLA identical related donor or matched unrelated donor.
•Unavailability of other therapeutic intervention that prolongs patient survival.
•No history of allergy to CAMPATH.
•The donor must be haploidentical with the recipient.
•Weight greater than or equal to 18 kg.
•Age between 2 and 60 years old.
•Negative two-way WBC crossmatch with the recipient.

•Major anticipated illness or organ failure incompatible with survival from transplantation.
•Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the transplantation procedure unlikely and making informed consent impossible.
•HIV positive
•Active infection
•Positive pregnancy test for women of childbearing age.
•Left ventricular ejection fraction less than 40%
•AST/SGOT greater than 20 x ULN (CTCAE grade IV v3.0)
•Bilirubin greater than 10 x ULN (CTCAE grade IV v3.0)
•Creatinine greater than 6 x ULN (CTCAE grade IV v 3.0)
•Pregnant or lactating
•Unfit to receive filgrastim (G-CSF) and undergo apheresis (abnormal blood counts, history of stroke, uncontrolled hypertension)
•Sickling hemoglobinopathies including HbSS, HbAS, HbSC
•HBsAg positive
•CMV positive (for CMV negative recipients)

发起方